Premium
Mereo BioPharma Group PLC (MREO)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with ad... Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0395 | 1.63866417756 | 2.4105 | 2.56 | 2.25 | 2056653 | 2.47859891 | CS |
| 4 | -0.66 | -21.2218649518 | 3.11 | 3.166 | 2.25 | 1518649 | 2.59828463 | CS |
| 12 | -1.29 | -34.4919786096 | 3.74 | 3.88 | 2.25 | 1311340 | 2.9963333 | CS |
| 26 | -2.08 | -45.9161147903 | 4.53 | 4.72 | 2.25 | 993052 | 3.41336427 | CS |
| 52 | -1.07 | -30.3977272727 | 3.52 | 5.02 | 2.25 | 1010195 | 3.51696011 | CS |
| 156 | 1.02 | 71.3286713287 | 1.43 | 5.02 | 0.301 | 1465922 | 1.96721315 | CS |
| 260 | 0.6 | 32.4324324324 | 1.85 | 5.02 | 0.301 | 1303610 | 2.34080815 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
